Intuitive Biosciences opened its doors in Fitchburg in March, and, led by a former TomoTherapy executive, wants to come out of the gate with a series of proven products. Intuitive plans to buy many of the assets of Gentel Biosciences, also of Fitchburg. The deal, whose terms have not been disclosed, is expected to finalize by the end of June, said Shawn Guse, Intuitive?s president and chief executive officer. Guse also is CEO of a separate biotech company, Apartia Pharmaceuticals, a startup based on UW-Madison research, aimed at developing a new class of antibiotics.
Office of Strategic Communication